Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Making A Market In Women’s Health: Endometriosis, Fibroids Emerge As Rx Targets

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.

You may also be interested in...



Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis

Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.

Actavis Flexes Its Commercial Muscles Ahead Of Allergan Integration

Before adding Allergan into the mix – and taking on its name – Actavis wants to show investors that it has a solid foundation as a growth pharma with strong brands in GI, CNS and women’s health.

Bayer’s “Next Wave” Of Products Will Reach Phase III Beachhead By 2015

In an interview, Bayer HealthCare’s recently-arrived new chief executive Olivier Brandicourt discusses the five assets that most excite the firm.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS005381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel